• Machine Learning for Senolytic Discovery

  2026-10-08

  Smer-Barreto and colleagues used machine learning trained on published data to identify three senolytic candidates—ginkgetin, periplocin, and oleandrin—and validated their activity in human cell models. The study shows how sparse, heterogeneous evidence can support lower-cost prioritization, while also highlighting why computational predictions require careful biological validation and should not be conflated with evidence for unrelated compounds such as Verteporfin.

• Porcupine Inhibition in Sclerosteosis

  2026-10-08

  A 2025 Bone Research study evaluates LGK-974 as a pharmacological strategy for sclerosteosis, an ultra-rare high-bone-mass disorder caused by loss of functional sclerostin. Using osteoblast and osteoclast assays plus Sost-deficient mice, the authors found reduced osteogenic activity and skeletal overgrowth, supporting PORCN inhibition as a preclinical approach while leaving important questions about sex-specific responses, safety, and human applicability.

• Nocodazole: Evidence in Cell-Cycle Research

  2026-10-07

  Nocodazole is widely described as a reversible microtubule polymerization inhibitor used to investigate cytoskeletal behavior and mitotic regulation. This overview separates established research context from supplier claims, examines its conceptual value in microtubule dynamics research and anticancer drug evaluation, and explains why findings involving cell-cycle perturbation require careful interpretation.

• MRF–FSHR Signaling in BMSC Osteogenesis

  2026-10-07

  A 2025 study identifies lncRNA MRF as a negative regulator of bone marrow mesenchymal stromal cell osteogenesis, linking its activity to FSHR and the cAMP–PKA–CREB pathway. The findings connect molecular perturbation in BMSCs with improved bone-defect ossification in mice, while leaving important questions about direct molecular interactions and clinical transferability.

• A40926: Context, Mechanism, and Evidence

  2026-10-06

  A source-grounded overview of A40926 as a natural glycopeptide and dalbavancin precursor, covering its reported mechanism, antibacterial findings, conceptual research applications, evidence strength, and limitations. The discussion distinguishes supplier-reported data from peer-reviewed clinical or systematic-review evidence.

• Verteporfin (CL 318952): Evidence and Context

  2026-10-06

  Verteporfin, also indexed in some research contexts as CL 318952, is a porphyrin-derived photosensitizer with established relevance to photodynamic therapy for ocular neovascularization and expanding experimental use in cell-death, autophagy, and cancer-biology studies. This overview separates supplier-reported claims from findings in the supplied Developmental Cell manuscript, compares evidence strength, and defines the limits of applying Verteporfin observations across models.

• IR-820 and Near-Infrared Biomedical Research

  2026-10-05

  IR-820, also marketed as New Indocyanine Green, is positioned as a near-infrared research dye for vascular and tumor imaging. However, the supplied melanoma study evaluated indocyanine green within a multifunctional nanoparticle rather than IR-820 itself. This overview separates catalog claims from published evidence and examines applications, interpretation, and translational limits.

• PA-824 and the Respiratory Logic of TB Killing

  2026-10-05

  PA-824 is a bicyclic nitroimidazole derivative whose tuberculosis activity links cell-wall disruption with respiratory stress. This article interprets recent pretomanid evidence through terminal oxidase biology, emphasizing what the findings establish, what remains uncertain, and how to evaluate the compound as a tuberculosis research compound.

• Verteporfin (CL 318952): Evidence and Limits

  2026-10-04

  Verteporfin, also known as CL 318952, is a photosensitizer with established relevance to photodynamic therapy for selected ocular neovascularization. Evidence for light-independent autophagy inhibition and broader oncology or regenerative applications remains model-dependent and should not be treated as equivalent to clinical efficacy.

• Linoleic Acid: Membrane Lipid to Metabolic Signal

  2026-10-03

  Linoleic Acid, or C18:2(9Z,12Z), is more than a membrane component or oxidative-stress reagent. This evidence-led analysis connects its redox, biophysical, and metabolic roles to recent findings on fatty-acid signaling and selective translation while defining important limits for interpreting research models.

• OTUD3–SLC7A11 Axis in Sunitinib Resistance

  2026-10-02

  The reference study identifies OTUD3-mediated deubiquitination of SLC7A11 as a mechanistic driver of sunitinib resistance in clear cell renal cell carcinoma. By preserving cystine uptake, glutathione production, and redox protection, the OTUD3–SLC7A11 axis suppresses lipid peroxidation and ferroptosis, suggesting a rationale for restoring ferroptotic sensitivity during treatment.

• Annexin V-Cy5/DAPI Apoptosis Kit Workflow

  2026-10-01

  Build a rapid cell-death workflow that separates viable, early apoptotic, late apoptotic, and necrotic populations in one assay. The approach is especially useful for connecting drug-response phenotypes with the calcium, mitochondrial, and PI3K/Akt findings reported in Ph+ ALL research.

• Dual HER2–VEGFR2 Targeting in TNBC

  2026-10-01

  A 2026 study examined lapatinib and Telatinib in HER2-negative MDA-MB-231 triple-negative breast cancer cells, linking combined kinase inhibition with reduced proliferation, invadopodia formation, and two-dimensional angiogenic tube formation. The work provides a phenotype-centered rationale for dual-pathway investigation while leaving target engagement, pharmacological synergy, and in vivo relevance unresolved.

• Acetylcholine Chloride in Gut-Brain Circuit Science

  2026-09-30

  Acetylcholine Chloride provides a chemically defined reference point for studying how gut-derived signals engage cholinergic circuits. This article translates recent Bacteroides fragilis findings into a compartment-aware framework for interpreting receptor, vagal, and seizure-related data without mistaking direct acetylcholine exposure for microbiota-mediated physiology.

• Gene-Modulating Therapies for ATTR Cardiomyopathy

  2026-09-30

  This 2025 mini-review explains how siRNA, antisense oligonucleotides, and CRISPR-Cas9 move transthyretin amyloid cardiomyopathy treatment from protein stabilization toward suppression or permanent disruption of hepatic TTR production. Its practical contribution is a mechanism-to-clinical-evidence framework that clarifies therapeutic promise while emphasizing unresolved questions about durability, safety, and comparative effectiveness.

8085 records 1/539 page Next 12345 下5页 Last page